Thiotepa

塞替派

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameThiotepa
Drug Alias Name硫涕巴Thiotepum塞替哌Tiotepa噻替派 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsRejection of organ transplantationCentral Nervous System LymphomaCommon Variable Immunodeficiency +[26] 
Global Approved IndicationsUrinary Bladder NeoplasmsOvarian NeoplasmsStomach Neoplasms +[8] 
Approved Indications in ChinaUrinary Bladder NeoplasmsOvarian NeoplasmsStomach Neoplasms +[7] 
Original Approved Country/TerritoryUnited States
Original Approved Date1959/03/09
Country/TerritoryUnited StatesEUMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesKaixin Pharmaceuticals IncUniversity Of FloridaAdienne Sa +[6] 
Inactive CompaniesImmunex
Active IndicationsRejection of organ transplantationCentral Nervous System LymphomaCommon Variable Immunodeficiency +[26] 
Inactive IndicationsN/A

Other Information

ATC CodeL01AC01
Related LinksWikipediaDrugBankKEGG